Advertisement
ABUS vs MGTX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Hold and MGTX is a Hold.
ABUS's Indicator enters downward trend
The Aroon Indicator for ABUS entered a downward trend on November 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 180 similar instances where the Aroon Indicator formed such a pattern. In 151 of the 180 cases the stock moved lower. This puts the odds of a downward move at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABUS as a result. In 63 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for ABUS turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 32 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABUS's RSI Indicator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABUS advanced for three days, in 183 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
ABUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ABUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.799) is normal, around the industry mean (3.498). P/E Ratio (4.627) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.400) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MGTX sees its Stochastic Oscillator recovers from oversold territory
On November 09, 2026, the Stochastic Oscillator for MGTX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 67 instances where the indicator left the oversold zone. In 61 of the 67 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MGTX's RSI Oscillator exited the oversold zone, 22 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on MGTX as a result. In 79 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for MGTX just turned positive on October 21, 2026. Looking at past instances where MGTX's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.
Following a +6.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGTX advanced for three days, in 213 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
MGTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for MGTX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. MGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.010) is normal, around the industry mean (3.498). P/E Ratio (10.112) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.715) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ABUS | MGTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 67 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 15 | 16 | |
PRICE GROWTH RATING 1..100 | 73 | 62 | |
P/E GROWTH RATING 1..100 | 59 | 78 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABUS's Valuation (77) in the Biotechnology industry is in the same range as MGTX (83). This means that ABUS’s stock grew similarly to MGTX’s over the last 12 months.
ABUS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MGTX (100). This means that ABUS’s stock grew similarly to MGTX’s over the last 12 months.
ABUS's SMR Rating (15) in the Biotechnology industry is in the same range as MGTX (16). This means that ABUS’s stock grew similarly to MGTX’s over the last 12 months.
MGTX's Price Growth Rating (62) in the Biotechnology industry is in the same range as ABUS (73). This means that MGTX’s stock grew similarly to ABUS’s over the last 12 months.
ABUS's P/E Growth Rating (59) in the Biotechnology industry is in the same range as MGTX (78). This means that ABUS’s stock grew similarly to MGTX’s over the last 12 months.
| ABUS | MGTX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 82% | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 77% | 1 day ago 82% |
| MACD ODDS (%) | 1 day ago 71% | 1 day ago 85% |
| TrendWeek ODDS (%) | 1 day ago 76% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 74% | 1 day ago 82% |
| Advances ODDS (%) | 1 day ago 73% | 1 day ago 83% |
| Declines ODDS (%) | 6 days ago 76% | 7 days ago 83% |
| BollingerBands ODDS (%) | 1 day ago 74% | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 84% | 1 day ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABUS’s FA Score shows that 1 FA rating(s) are green while MGTX’s FA Score has 1 green FA rating(s).
- ABUS’s FA Score: 1 green, 4 red.
- MGTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABUS’s TA Score shows that 4 TA indicator(s) are bullish while MGTX’s TA Score has 6 bullish TA indicator(s).
- ABUS’s TA Score: 4 bullish, 4 bearish.
- MGTX’s TA Score: 6 bullish, 2 bearish.
Price Growth
ABUS (@Biotechnology) experienced а -1.55% price change this week, while MGTX (@Biotechnology) price change was +1.05% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.36%. For the same industry, the average monthly price growth was -9.96%, and the average quarterly price growth was +79.71%.
Reported Earning Dates
ABUS is expected to report earnings on Nov 12, 2026.
MGTX is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-0.36% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ABUS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with RCKT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then RCKT could also see price increases.
| Ticker / NAME | Correlation To ABUS | 1D Price Change % | ||
|---|---|---|---|---|
| ABUS | 100% | +2.69% | ||
| RCKT - ABUS | 45% Loosely correlated | -3.16% | ||
| MGTX - ABUS | 44% Loosely correlated | +1.37% | ||
| PCVX - ABUS | 43% Loosely correlated | -1.73% | ||
| ARRY - ABUS | 43% Loosely correlated | -8.86% | ||
| AXON - ABUS | 42% Loosely correlated | -0.21% | ||
More | ||||
MGTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, MGTX has been loosely correlated with EDIT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if MGTX jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To MGTX | 1D Price Change % | ||
|---|---|---|---|---|
| MGTX | 100% | +1.37% | ||
| EDIT - MGTX | 58% Loosely correlated | -8.91% | ||
| SANA - MGTX | 55% Loosely correlated | -1.42% | ||
| KURA - MGTX | 53% Loosely correlated | N/A | ||
| VYGR - MGTX | 51% Loosely correlated | -8.29% | ||
| TSHA - MGTX | 51% Loosely correlated | -2.17% | ||
More | ||||